ABSTRACT
NELFINAVIR Trade name: Viracept (Pfizer) Indications: HIV infection Class: Antiretroviral, CYP3A4 inhibitor, Protease inhibitor, HIV Half-life: 3.5-5 hours Clinically important, potentially hazardous interactions with: abiraterone, afatinib, alfuzosin, amiodarone, amprenavir, aripiprazole, artemether / lumefantrine, atorvastatin, avanafil, barbiturates, benzodiazepines, cabazitaxel, cabozantinib, carbamazepine, chlordiazepoxide, ciclesonide, clonazepam, clorazepate, crizotinib, cyclosporine, darifenacin, dasatinib, delavirdine, diazepam, dihydroergotamine, eletriptan, eplerenone, ergot alkaloids, ergotamine, erlotinib, estrogens, eszopiclone, etravirine, eucalyptus, everolimus, fentanyl, fesoterodine, flurazepam, fluticasone propionate, indinavir, ivabradine, ixabepilone, lapatinib, lomitapide, lopinavir, lorazepam, maraviroc, methadone, methylergonovine, methysergide, midazolam, mifepristone, omeprazole, oral contraceptives, oxazepam, paclitaxel, pantoprazole, pazopanib, phenytoin, pimozide, ponatinib, primidone, progestogens, quazepam, quinidine, quinine, ranolazine, rifabutin, rifampin, rilpivirine, ritonavir, rivaroxaban, romidepsin, rosuvastatin, ruxolitinib, saquinavir, sildenafil, simeprevir, simvastatin, solifenacin, St John’s wort, sunitinib, tacrolimus, tadalafil, telithromycin, temazepam, temsirolimus, ticagrelor, tolterodine, tolvaptan, vardenafil, vemurafenib Pregnancy category: B Note: Protease inhibitors cause dyslipidemia which includes elevated triglycerides and cholesterol and redistribution of body fat centrally to produce the so-called ‘protease paunch’, breast enlargement, facial atrophy, and ‘buffalo hump’.
